nach oben

Current Breast Cancer Reports

Erschienen in:

20.05.2016 | Biomarkers (S Dawood, Section Editor)

Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data

verfasst von: Sana Al-Sukhun, Isam Lataifeh, Rajaa Al-Sukhun

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

PIK3CA is one of the most commonly mutated oncogenes in breast cancer, albeit at variable distribution among the different biological subtypes. Overall, it appears that PIK3CA mutations are most likely found in tumors with less aggressive characteristics, especially estrogen receptor (ER)-positive, luminal A tumors. Studies assessing its prognostic or predictive role have reported conflicting data, in part due to different methodologies used for detection and small sample sizes. The majority of reports used retrospective data from clinical trials thus could not exclude the effect of treatment heterogeneity when evaluating prognostic factors, and analysis was not subtype specific. Since breast cancer subtypes differ in terms of biology, treatment, and outcomes, it is critical that the effects of PIK3CA mutations on pathophysiology and therapy responsiveness are analyzed independently in each subtype. This short review discusses these issues and the significance of PIK3CA mutations in relation to the expression of HER2 and hormone receptors.

Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.CrossRefPubMed

Katso R et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–75.CrossRefPubMed

Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7.CrossRefPubMed

Cantley LC et al. Oncogenes and signal transduction. Cell. 1991;64(2):281–302.CrossRefPubMed

Samuels Y et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.CrossRefPubMed

Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103(5):1475–9.CrossRefPubMedPubMedCentral

Philp AJ et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61(20):7426–9.PubMed

Zhao JJ et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102(51):18443–8.CrossRefPubMedPubMedCentral

Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010;107(16):7491–6.CrossRefPubMedPubMedCentral

10.

Kao GD et al. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem. 2007;282(29):21206–12.CrossRefPubMedPubMedCentral

11.

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef

12.

Stemke-Hale K et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–91.CrossRefPubMedPubMedCentral

13.

Cossu-Rocca P et al. Analysis of PIK3CA mutations and activation pathways in triple negative breast cancer. PLoS One. 2015;10(11):e0141763.CrossRefPubMedPubMedCentral

14.

Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3(1):27–34.CrossRefPubMedPubMedCentral

15.

Miled N et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317(5835):239–42.CrossRefPubMed

16.

Mihalcea CE et al. Particular molecular and ultrastructural aspects in invasive mammary carcinoma. Romanian J Morphol Embryol. 2015;56(4):1371–81.

17.

Barbareschi M et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13(20):6064–9.CrossRefPubMed

18.

Dogruluk T et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res. 2015;75(24):5341–54.CrossRefPubMed

19.

Papaxoinis G et al. Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS One. 2015;10(10):e0140293.CrossRefPubMedPubMedCentral

20.

Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102(3):802–7.CrossRefPubMedPubMedCentral

21.

Markou A et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res. 2014;20(22):5823–34.CrossRefPubMed

22.

Deng G et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014;14:456.CrossRefPubMedPubMedCentral

23.

Dupont Jensen J et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17(4):667–77.CrossRefPubMed

24.

Kalinsky K et al. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat. 2011;129(2):635–43.CrossRefPubMed

25.

Miron A et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010;70(14):5674–8.CrossRefPubMedPubMedCentral

26.

Sakr RA et al. PI3K pathway activation in high-grade ductal carcinoma in situ—implications for progression to invasive breast carcinoma. Clin Cancer Res. 2014;20(9):2326–37.CrossRefPubMedPubMedCentral

27.

Troxell ML et al. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Mod Pathol. 2012;25(7):930–7.CrossRefPubMed

28.

Saal LH et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65(7):2554–9.CrossRefPubMed

29.

Pang B et al. Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep. 2014;4:6255.CrossRefPubMedPubMedCentral

30.

Maruyama N et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13(2 Pt 1):408–14.CrossRefPubMed

31.

Cizkova M et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res. 2012;14(1):R28.CrossRefPubMedPubMedCentral

32.

Abramson VG et al. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat. 2014;145(2):389–99.CrossRefPubMedPubMedCentral

33.

Lopez-Knowles E et al. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res. 2014;16(3):R68.CrossRefPubMedPubMedCentral

34.

Beelen K et al. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res. 2014;16(1):R13.CrossRefPubMedPubMedCentral

35.

Sabine VS et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 2014;32(27):2951–8.CrossRefPubMed

36.

Liu YR et al. PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. Oncol Targets Ther. 2014;7:543–52.

37.

Ramirez-Ardila DE et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat. 2013;139(1):39–49.CrossRefPubMed

38.

Loi S et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010;107(22):10208–13.CrossRefPubMedPubMedCentral

39.

Knuefermann C et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205–12.CrossRefPubMed

40.

Bosch A et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7(283):283ra51.CrossRefPubMedPubMedCentral

41.

Loi S et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One. 2013;8(1):e53292.CrossRefPubMedPubMedCentral

42.

Treilleux I et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol. 2015;26(1):120–5.CrossRefPubMed

43.

Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17(3):279–88.CrossRefPubMedPubMedCentral

44.

Loi S et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50.CrossRefPubMed

45.

Hanker AB et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013;110(35):14372–7.CrossRefPubMedPubMedCentral

46.

Berns K et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.CrossRefPubMed

47.

Loi S et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst. 2013;105(13):960–7.CrossRefPubMedPubMedCentral

48.

Pogue-Geile KL et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 2015;33(12):1340–7.CrossRefPubMedPubMedCentral

49.

Majewski IJ et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 2015;33(12):1334–9.CrossRefPubMed

50.

Loibl S et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32(29):3212–20.CrossRefPubMed

51.

Baselga J et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.CrossRefPubMed

52.

Goel S, Krop IE. Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2015;33(12):1407–9.CrossRefPubMed

53.

Chakrabarty A et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013;73(3):1190–200.CrossRefPubMedPubMedCentral

54.

Brough R et al. Functional viability profiles of breast cancer. Cancer Discov. 2011;1(3):260–73.CrossRefPubMedPubMedCentral

55.

Andre F et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91.CrossRefPubMed

56.

Hurvitz SA et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816–29.CrossRefPubMed

57.

Kriegsmann M et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget. 2014;5(20):9952–65.CrossRefPubMedPubMedCentral

58.

Boyault S et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 2012;132(1):29–39.CrossRefPubMed

59.

He J et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406–10.CrossRefPubMed

60.

Tang D et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2012;29(2):526–33.CrossRefPubMed

61.

Takeshita T et al. Clinical significance of androgen receptor and its phosphorylated form in breast cancer. Endocr Relat Cancer. 2013;20(5):L15–21.CrossRefPubMed

62.

Takeshita T et al. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci. 2015;106(11):1582–9.CrossRefPubMedPubMedCentral

63.

Lehmann BD et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.CrossRefPubMedPubMedCentral

64.

Eichhorn PJ et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68(22):9221–30.CrossRefPubMedPubMedCentral

65.

Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27(41):5511–26.CrossRefPubMed

66.

De P et al. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia. 2014;16(1):43–72.CrossRefPubMedPubMedCentral

Titel: Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data
verfasst von: Sana Al-Sukhun
Isam Lataifeh
Rajaa Al-Sukhun
Publikationsdatum: 20.05.2016
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 2/2016
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-016-0215-6

Springer Medizin

Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Role of Breast MRI in Patients with Newly Diagnosed Breast Cancer

Margins in Breast-Conserving Surgery for Early Breast Cancer: How Much is Good Enough?

New Developments in Assessing Risk of Local Recurrence in Patients with Ductal Carcinoma In Situ after Lumpectomy and Breast Radiation

Regional Nodal Radiotherapy in Early-Stage Breast Cancer: Where Are We in 2016?

Emerging Biomarkers of the Future: Changing Clinical Practice for 2020

The Optimal Approach to Post-Mastectomy and Post-Lumpectomy Breast Reconstruction

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie